CD19

CD19 is a surface glycoprotein of the immunoglobulin gene superfamily. It is expressed during all stages of B cell development until terminal plasma cell differentiation and is considered the earliest and broadest B-cell marker.

Most B cell cancers express normal or high levels of CD19, making it a useful biomarker for B-cell malignancies, including B cell lymphomas, acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Additionally, because CD19 expression is restricted to B cells and follicular dendritic cells, CD19 is a primary target for B cell lymphoma and leukemia therapies, such as bispecific antibodies and CAR-T cell therapies.

Imanis CD19 tumor antigen panels facilitate pre-clinical studies of CD19-targeted therapies by offering models with varied CD19 expression levels. Each panel includes a CD19 positive and CD19 negative cell line on the same cell background for controlled experiments in vitro or in vivo. To facilitate non-invasive tumor monitoring in vivo, all cells also express firefly luciferase.

Cell lines can be purchased individually or at a discounted rate as a group. More cell lines to be added soon.